TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29368069

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with red, 655-nm laser light, 150 mW, 2 J/cm2, on days 0, 3, 5, and 7
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no laser therapy)
Number of subjects: 11
Study: 26784710

Group type: EXPERIMENTAL
Intervention: Vistakon Acuvue Bifocal (bifocal soft contact lenses [BFSCLs])
Number of subjects: 86

Group type: COMPARATOR
Intervention: Vistakon Acuvue 2 (single‐vision soft contact lenses [SVSCLs])
Number of subjects: 86
Study: 23763411

Group type: EXPERIMENTAL
Intervention: Healthy Mothers on the Move (MOMs) intervention
Number of subjects: 139

Group type: COMPARATOR
Intervention: Minimal Intervention (MI)
Number of subjects: 139
Study: 21880544

Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 19546072

Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/day orally for 2 weeks before surgery)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 30
Study: 17635062

Group type: EXPERIMENTAL
Intervention: Systemic warming using the Inditherm warming mattress set at 40 degrees C
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard antibiotic and fluid resuscitation (Control)
Number of subjects: 33
Study: 15726917

Group type: EXPERIMENTAL
Intervention: Estradiol (1 mg oral)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 12046257

Group type: EXPERIMENTAL
Intervention: Powder form of calcium carbonate (Vitacalcin pulvis)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Effervescent tablet (Calcium 500 mg Pharmavit)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Milk (250 ml enriched with milk calcium complex)
Number of subjects: 24
Study: 9468366

Group type: EXPERIMENTAL
Intervention: ZDV 200 mg three times daily plus p24‐VLP (500 microg) in intramuscular alum monthly
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ZDV 200 mg three times daily plus intramuscular administration of alum adjuvant monthly
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo capsules plus p24‐VLP (500 microg) in intramuscular alum monthly
Number of subjects: 61
Study: 7589843

Group type: EXPERIMENTAL
Intervention: Increased fasting insulin (quartile 4, high)
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Decreased delta I30/delta G30 (quartile 1, low)
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Increased fasting insulin and decreased delta I30/delta G30
Number of subjects: 714
Study: 2202010

Group type: EXPERIMENTAL
Intervention: Dopamine infusion for 12 hours during arteriography
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo infusion during arteriography
Number of subjects: 60
Study: 326133

Group type: EXPERIMENTAL
Intervention: 6% dextran 70 (Macrodex)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: 10% dextran 40 (Rhemacrodex)
Number of subjects: 235

Group type: COMPARATOR
Intervention: 5% dextrose in 0.9% saline (Control)
Number of subjects: 235
Study: 31977595

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus lamivudine (2DR)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Dolutegravir plus tenofovir disoproxil fumarate/emtricitabine (3DR)
Number of subjects: 293
Study: 31243557

Group type: EXPERIMENTAL
Intervention: Occiput-to-wall distance (OWD)
Number of subjects: 158
Study: 28041700

Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg once daily for six months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Enalapril 20mg once daily for six months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 80
Study: 26180950

Group type: EXPERIMENTAL
Intervention: Cafeteria-based intervention with signage promoting water and disposable cups near water sources
Number of subjects: 10
Study: 23613224

Group type: EXPERIMENTAL
Intervention: Treadmill exercise (TE)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group exercise (GE)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Home-based exercise (HE)
Number of subjects: 90
Study: 21562072

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (wP, 80 mg/m(2)/week)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel + carboplatin (wP + C, AUC 5 mg/ml/min every 4 weeks)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel + topotecan (wP + wT, 3 mg/m(2)/week)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control (monotherapy vs combination therapy)
Number of subjects: 165
Study: 19686934

Group type: EXPERIMENTAL
Intervention: rhBMP‐2/ACS
Number of subjects: 160

Group type: COMPARATOR
Intervention: Autogenous bone graft
Number of subjects: 160
Study: 17049882

Group type: EXPERIMENTAL
Intervention: Rotating spot method with instructions to report the instant when the finger movement was initiated
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotating spot method with instructions to report the instant when the finger movement was completed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotating spot method with altered physical characteristics of the spot or clock face
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotating spot method with altered instructions given to the participant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responses made by different subjects
Number of subjects: 0
Study: 15161770

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 54

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 54
Study: 11862589

Group type: EXPERIMENTAL
Intervention: Basiliximab (40 mg, two 20 mg bolus injections on days 0 and 4)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Basiliximab (40 mg)
Number of subjects: 381
Study: 10215945

Group type: EXPERIMENTAL
Intervention: Malmö Treatment Model protocol including immunoadsorption, cyclophosphamide (12-15 mg/kg bw intravenously for 2 days, then 2-3 mg/kg bw orally for 8-10 days), and intravenous gammaglobulin (0.4 g/kg bw daily for 5 days)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Malmö Treatment Model protocol
Number of subjects: 23
Study: 7611753

Group type: EXPERIMENTAL
Intervention: AO‐90 amino acid solution (methionine-depleting TPN) with 5‐FU and MMC
Number of subjects: 14

Group type: COMPARATOR
Intervention: Amiparen (commercial methionine and cysteine containing amino acid solution) with 5‐FU and MMC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: AO‐90 amino acid solution (methionine-depleting TPN) with 5‐FU for 7 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Amiparen (commercial methionine and cysteine containing amino acid solution) with 5‐FU for 7 days
Number of subjects: 14
Study: 2307275

Group type: EXPERIMENTAL
Intervention: Zinc oxide (25%) medicated occlusive dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control-treated skin
Number of subjects: 0
Study: 80632

Group type: EXPERIMENTAL
Intervention: Ancrod (5 daily subcutaneous injections)
Number of subjects: 53
Study: 31999405

Group type: EXPERIMENTAL
Intervention: Hijamat (wet cupping therapy) plus standard lifestyle modification
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (standard lifestyle modification only)
Number of subjects: 120
Study: 30229691

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (face-to-face nutrition, physical activity, and stress management) for 12 months
Number of subjects: 95

Group type: COMPARATOR
Intervention: Remotely delivered intervention (general cancer prevention)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII) quartile 4
Number of subjects: 95
Study: 28714336

Group type: EXPERIMENTAL
Intervention: Plasma oxylipins
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Plasma fatty acids
Number of subjects: 98
Study: 26506936

Group type: EXPERIMENTAL
Intervention: Hybrid interrupted‐continuous suturing technique
Number of subjects: 78

Group type: COMPARATOR
Intervention: Continuous suturing technique
Number of subjects: 78
Study: 25856266

Group type: EXPERIMENTAL
Intervention: Supported employment vocational rehabilitation program (Spinal Cord Injury‐Vocational Integration Program)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 157
Study: 22971205

Group type: EXPERIMENTAL
Intervention: Pharmacist-led pharmaceutical care intervention program
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 171
Study: 19534671

Group type: EXPERIMENTAL
Intervention: Bovine intestinal alkaline phosphatase
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 17707296

Group type: EXPERIMENTAL
Intervention: Re‐Mission video game
Number of subjects: 375

Group type: COMPARATOR
Intervention: Regular commercial game (control)
Number of subjects: 375
Study: 15125352

Group type: EXPERIMENTAL
Intervention: Esmolol 150 mcg/kg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Nicardipine 15 mcg/kg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mg/kg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 11208845

Group type: EXPERIMENTAL
Intervention: RT-PCV (radiotherapy plus procarbazine, lomustine, and vincristine)
Number of subjects: 674

Group type: COMPARATOR
Intervention: RT (radiotherapy alone)
Number of subjects: 674
Study: 9928562

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (CT) and reduced-dose radiation therapy (RT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (CT) and full-dose radiation therapy (RT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy starting with chemotherapy (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initiating radiation therapy (RT) sooner
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current treatment regimens delivering CT in a short time period (Adriamycin and Cytoxan in four 3-week cycles)
Number of subjects: 0
Study: 7697784

Group type: EXPERIMENTAL
Intervention: Psycho-educational groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skills teaching
Number of subjects: 0
Study: 3300561

Group type: EXPERIMENTAL
Intervention: Regimen A: metoclopramide (1mg/kg i.v. every 8 h X 3)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Regimen B: metoclopramide and droperidol (2.5 mg i.v. every 8 h X 3)
Number of subjects: 32
Study: 30032828

Group type: EXPERIMENTAL
Intervention: Escalated therapy (B) with radiation dose up to 84 Gy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard treatment (A) with radiation dose of 68 Gy
Number of subjects: 36
Study: 27196986

Group type: EXPERIMENTAL
Intervention: Enhanced care (nurses permitted to provide hormonal contraceptives postpartum)
Number of subjects: 337
Study: 25316134

Group type: EXPERIMENTAL
Intervention: Biophysical therapy (Med Select 729)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 21995867

Group type: EXPERIMENTAL
Intervention: Brisk walking (20 min semi‐self‐paced)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Passive control (sitting with the opportunity of reading)
Number of subjects: 16
Study: 20923992

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including interactive voice response technology, home BP monitoring, and pharmacist-led BP management
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 146
Study: 18931236

Group type: EXPERIMENTAL
Intervention: NPPV (pressure support = 8 cm H2O, positive end-expiratory pressure = 6 cm H2O)
Number of subjects: 28

Group type: COMPARATOR
Intervention: SV (spontaneous ventilation)
Number of subjects: 28
Study: 16447669

Group type: EXPERIMENTAL
Intervention: Acupuncture group with bilateral Neiguan (P 6) needled for 3 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Medication group given 20 mL of Shenmai Injectio intravenously for 6 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Comparison with healthy subjects
Number of subjects: 49
Study: 12476043

Group type: EXPERIMENTAL
Intervention: Esberitox N
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 10740459

Group type: EXPERIMENTAL
Intervention: OP-1 device
Number of subjects: 12

Group type: COMPARATOR
Intervention: Autogenous bone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Demineralized bone matrix (DBM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No graft (control group)
Number of subjects: 12
Study: 8526449

Group type: EXPERIMENTAL
Intervention: polyglactine 910
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: polydioxanone I
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: polydioxanone II
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: all sutures
Number of subjects: 235
Study: 8248611

Group type: EXPERIMENTAL
Intervention: Propofol (1-1.5 mg/kg) administered before retrobulbar anesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no propofol)
Number of subjects: 80
Study: 2935243

Group type: EXPERIMENTAL
Intervention: Hepatic resection plus continuous hepatic artery infusion (CHAI) of fluorodeoxyuridine (FUDR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CHAI only
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hepatic resection plus CHAI
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CHAI for patients with positive portal nodes
Number of subjects: 100

Group type: COMPARATOR
Intervention: CHAI for patients with unresectable disease
Number of subjects: 100
Study: 29796967

Group type: EXPERIMENTAL
Intervention: Postnatal physical IPV
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Infant HIV serostatus
Number of subjects: 72
Study: 27551936

Group type: EXPERIMENTAL
Intervention: New Ball (NB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Ball (SB)
Number of subjects: 0
Study: 24528927

Group type: EXPERIMENTAL
Intervention: T12PR24 (12-week telaprevir with 24-week peginterferon alfa-2a/ribavirin)
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: T12PR48 (12-week telaprevir with 48-week peginterferon alfa-2a/ribavirin)
Number of subjects: 1147

Group type: COMPARATOR
Intervention: PR48 with placebo (48-week peginterferon alfa-2a/ribavirin)
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1147
Study: 22575076

Group type: EXPERIMENTAL
Intervention: Baker's yeast β-glucan (250 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (rice flour)
Number of subjects: 60
Study: 21910332

Group type: EXPERIMENTAL
Intervention: Needling + Fluoxetine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Needling
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hamilton's depression scale
Number of subjects: 42
Study: 17391911

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for fear of flying, 8 sessions
Number of subjects: 115

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 115
Study: 17238470

Group type: EXPERIMENTAL
Intervention: Technology assisted pharmacist intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (standard practice)
Number of subjects: 0
Study: 12679475

Group type: EXPERIMENTAL
Intervention: GH treatment (n=8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo treatment (n=8)
Number of subjects: 16
Study: 11129745

Group type: EXPERIMENTAL
Intervention: ACE intervention
Number of subjects: 1531

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1531
Study: 8919832

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.4 mg/kg administered 10 min before induction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ketorolac 0.4 mg/kg administered 5 min after decollement of nasal septum
Number of subjects: 30
Study: 2262623

Group type: EXPERIMENTAL
Intervention: microlipoinjection
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: injectable collagen
Number of subjects: 18
Study: 6117988

Group type: EXPERIMENTAL
Intervention: 5 mg bunitrolol (Stresson)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20 mg bunitrolol (Stresson)
Number of subjects: 20
Study: 31642408

Group type: EXPERIMENTAL
Intervention: Neurological music therapy intervention for 3 months (AB group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neurological music therapy intervention for 3 months (BA group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (AB and BA) during intervention period
Number of subjects: 40
Study: 31396693

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) subcutaneous administration
Number of subjects: 449
Study: 28276192

Group type: EXPERIMENTAL
Intervention: 10 mg of medroxyprogesterone acetate (MPA) per day
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 4 mg of medroxyprogesterone acetate (MPA) per day
Number of subjects: 300
Study: 25595151

Group type: EXPERIMENTAL
Intervention: rhEPO 40,000 IU fortnightly
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 24777678

Group type: EXPERIMENTAL
Intervention: Ipilimumab treatment
Number of subjects: 5
Study: 20957399

Group type: EXPERIMENTAL
Intervention: Parecoxib 80 mg daily i.v.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lornoxicam 16 mg daily i.v.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Diclofenac 150 mg daily i.m.
Number of subjects: 3
Study: 18795893

Group type: EXPERIMENTAL
Intervention: Oral antioxidants (vitamins C and E, and alpha‐lipoic acid)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Knee‐extensor exercise training
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Antioxidant administration after exercise training
Number of subjects: 6
Study: 16970165

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg once a day for 8 weeks
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 15137556

Group type: EXPERIMENTAL
Intervention: Music-based exercise programme (daily physical exercises supported by music for 30 min/session for three months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (daily conversation for the same duration)
Number of subjects: 25
Study: 10806470

Group type: EXPERIMENTAL
Intervention: Music assisted progressive muscle relaxation (M + PMR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Music listening
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Silence/suggestion
Number of subjects: 60
Study: 9314469

Group type: EXPERIMENTAL
Intervention: Vancomycin (125 mg perorally four times daily for 7 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 20
Study: 8174198

Group type: EXPERIMENTAL
Intervention: BH‐AC.DMP (daunorubicin, 6‐mercaptopurine, and prednisolone)
Number of subjects: 433

Group type: COMPARATOR
Intervention: BH‐AC.AMP (aclarubicin, 6‐mercaptopurine, and prednisolone)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: BH‐AC.DMP (for subtype M3)
Number of subjects: 433

Group type: COMPARATOR
Intervention: BH‐AC.AMP (for subtype M3)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: BH‐AC.DMP (for subtypes M1, M2, M4, and M5)
Number of subjects: 433

Group type: COMPARATOR
Intervention: BH‐AC.AMP (for subtypes M1, M2, M4, and M5)
Number of subjects: 433
Study: 3295321

Group type: EXPERIMENTAL
Intervention: Cefixime (CFIX)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Cefaclor (CCL)
Number of subjects: 245
Study: 31461222

Group type: EXPERIMENTAL
Intervention: Axillary dissection after positive sentinel node biopsy
Number of subjects: 126

Group type: COMPARATOR
Intervention: No axillary dissection
Number of subjects: 126
Study: 31874283

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 μg
Number of subjects: 2926

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5 μg
Number of subjects: 2926
Study: 29294360

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once-daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 μg once-daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Glycopyrronium 44 μg once-daily
Number of subjects: 16
Study: 28872637

Group type: EXPERIMENTAL
Intervention: 4 weeks of intensive CBT
Number of subjects: 43

Group type: COMPARATOR
Intervention: 4 weeks waitlist followed by 4 weeks of CBT
Number of subjects: 43

Group type: COMPARATOR
Intervention: 24 healthy controls before and after 4 weeks of no treatment
Number of subjects: 43
Study: 26614277

Group type: EXPERIMENTAL
Intervention: CBT-I
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CBT-I-D
Number of subjects: 150

Group type: COMPARATOR
Intervention: PCG
Number of subjects: 150
Study: 22902063

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 21962422

Group type: EXPERIMENTAL
Intervention: Brain Fitness intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Health education active control intervention
Number of subjects: 40
Study: 18382875

Group type: EXPERIMENTAL
Intervention: Polypropylene tape (TVT‐O) placed underneath the bladder base during anterior colporrhaphy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no polypropylene tape)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (study and control)
Number of subjects: 50
Study: 17416954

Group type: EXPERIMENTAL
Intervention: Topical 0.5% proparacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subtenon 2% lidocaine
Number of subjects: 0
Study: 12749495

Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (compounds without ITNs)
Number of subjects: 0
Study: 11099451

Group type: EXPERIMENTAL
Intervention: Split-brain patients
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Split-brain patients (pre- and post-callosotomy)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Normal and epileptic controls
Number of subjects: 4
Study: 8624657

Group type: EXPERIMENTAL
Intervention: 585-nm pulsed dye laser treatment with 10-mm spot size and 3.0 J/cm2 fluence
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 585-nm pulsed dye laser treatment (all protocols)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 585-nm pulsed dye laser treatment
Number of subjects: 39
Study: 1729110

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (FIO2 of 0.30)
Number of subjects: 22